Cargando…
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure
BACKGROUND: Sacubitril valsartan and valsartan are the first new drugs approved for angiotensin receptor neprilysin lysine inhibitors (ARNIs) in outpatients with chronic heart failure (CHF) and hypertension. Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mo...
Autores principales: | Du, Haiping, Li, Xiao, Zhao, Weifang, Jiang, Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881145/ https://www.ncbi.nlm.nih.gov/pubmed/35222898 http://dx.doi.org/10.1155/2022/9494981 |
Ejemplares similares
-
The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)